A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

NCT01458288 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Non-hodgkin's Lymphoma
Hodgkin's Disease

Interventions

DRUG: TG-0054

Sponsor

GPCR Therapeutics, Inc.